The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-07 and is reviewed periodically as new material appears.
Aseptic technique reduces microbial and particulate contamination when a peptide solution will be used in cell culture or other sensitive applications. Work in a clean area, use sterile containers and filtered tips, and avoid touching vial interiors. Preparing aliquots immediately after dissolution limits repeated temperature cycling, which is a common cause of aggregation and activity loss. Low-binding plastic tubes are preferred for peptides that adsorb to surfaces, especially hydrophobic or positively charged sequences. Labels should record identity, solvent, concentration, and preparation date so that later use can be traced.
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder or frozen solution | Powder typically more stable for long-term storage; solutions require colder conditions. |
| Recommended reconstitution solvent | Water, buffer, or water-miscible organic solvent | Matches peptide hydrophobicity; test small portion if unknown. |
| Typical working aliquot size | Single-use volumes in low-binding tubes | Reduces repeated warming and cooling and contamination risk. |
| Short-term shipping condition | Dry ice for frozen solutions; gel packs for powders | Insulation and temperature logging help document transit. |
| Common purity check | Reverse-phase HPLC with UV detection | Often paired with mass spectrometry for identity confirmation. |
Reconstitution is often performed with sterile water, buffer, or a water-miscible organic solvent, depending on solubility. The solvent should be added gently along the vial wall, and the solution mixed by gentle swirling rather than vigorous vortexing, which can cause foaming and surface denaturation. Some sequences require a small amount of base or acid to dissolve, followed by pH adjustment. Preparing a concentrated stock solution can simplify later dilution, but the stock itself may have limited stability. Records of solvent, concentration, and date support reproducibility.
After reconstitution, dividing the solution into single-use aliquots limits multiple warming and cooling events and reduces contamination risk. Low-binding polypropylene tubes are often preferred because peptides can adsorb to glass or untreated plastic surfaces. Filling headspace with nitrogen or argon can slow oxidation, and amber or foil-wrapped containers reduce photodegradation. Each aliquot should be labeled with peptide identity, concentration, date, and storage conditions. Frozen aliquots should be thawed quickly and kept on ice until use.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
Temperature is a primary variable because most degradation reactions slow as thermal energy decreases. Lyophilized powders are commonly held at -20 °C for routine work and at -80 °C for longer archival periods, though exact recommendations depend on the peptide. Solutions are less stable than dry powders in many cases, and repeated freeze-thaw cycles can promote aggregation or precipitation. Inert atmospheres, such as argon or nitrogen, can limit oxidation for oxygen-sensitive sequences. Desiccants reduce water activity, which lowers hydrolysis rates during storage.
Light exposure can damage aromatic residues and certain labels, so amber vials or opaque containers are often used. pH control matters in solution, as extreme acidity or alkalinity accelerates backbone cleavage; buffers may also introduce ions that affect solubility. Microbial growth is a concern for aqueous preparations that lack preservatives, though many research peptides are handled in sterile or low-bioburden conditions. Container materials can adsorb peptides, particularly hydrophobic or positively charged sequences, reducing recovery. These factors interact, meaning storage decisions balance chemical stability, physical state, and intended use.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, and conformation. The amide backbone can hydrolyze under acidic or basic conditions, while side chains such as methionine, cysteine, and tryptophan are prone to oxidation. Aggregation may occur when hydrophobic regions associate, especially near surfaces or at high concentration. Because these pathways differ among peptides, no single storage condition applies to all sequences. Stability studies therefore examine each peptide under defined temperature, pH, and humidity ranges.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
=== Cultivator model === Beyond "ORF-first" and "transcription-first" scenarios, the proposed "cultivator model" emphasises that selection acting on regulatory environments of nearby pre-existing genes can promote stepwise fixation of new transcripts and, more rarely, protein-coding de novo genes.
Flaps may include skin in their construction. Skin is important for many reasons, but its role in thermoregulation, immune function, and blood supply aid in flap survival. The skin can be divided into three main layers: the epidermis, dermis, and subcutaneous tissue. Blood is mainly supplied to the skin by two networks of blood vessels. The deep network lies between the dermis and the subcutaneous tissue, while the shallow network lies within the papillary layer of the dermis. The epidermis is supplied by diffusion from this shallow network and both networks are supplied by collaterals, and by perforating arteries that bring blood from deeper layers either between muscles (septocutaneous perforators) or through muscles (musculocutaneous perforators). This robust and redundant blood supply is important in flap surgery, because flaps are cut off from other blood vessels when they are raised and removed from surrounding native tissue. The remaining blood supply must then keep the tissue alive until additional blood supply can be formed through angiogenesis.
=== Examples === As enzymes have evolved to bind their substrates tightly, and most reversible inhibitors bind in the active site of enzymes, it is unsurprising that some of these inhibitors are strikingly similar in structure to the substrates of their targets. Inhibitors of dihydrofolate reductase (DHFR) are prominent examples. Other examples of these substrate mimics are the protease inhibitors, a therapeutically effective class of antiretroviral drugs used to treat HIV/AIDS. The structure of ritonavir, a peptidomimetic (peptide mimic) protease inhibitor containing three peptide bonds, as shown in the "competitive inhibition" figure above. As this drug resembles the peptide that is the substrate of the HIV protease, it competes with the substrate in the enzyme's active site. Enzyme inhibitors are often designed to mimic the transition state or intermediate of an enzyme-catalysed reaction. This ensures that the inhibitor exploits the transition state stabilising effect of the enzyme, resulting in a better binding affinity (lower Ki) than substrate-based designs. An example of such a transition state inhibitor is the antiviral drug oseltamivir; this drug mimics the planar nature of the ring oxonium ion in the reaction of the viral enzyme neuraminidase. However, not all inhibitors are based on the structures of substrates. For example, the structure of another HIV protease inhibitor tipranavir is not based on a peptide and has no obvious structural similarity to a protein substrate.
== External links == "Opioid Receptors: μ". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. mu+Opioid+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human OPRM1 genome location and OPRM1 gene details page in the UCSC Genome Browser.
=== Comparing PAM and BLOSUM === Although the PAM log-odds matrices were the first scoring matrices used with BLAST, the PAM matrices have largely been replaced by the BLOSUM matrices. Although both matrices produce similar scoring outcomes they were generated using differing methodologies. The BLOSUM matrices were generated directly from the amino acid differences in aligned blocks that have diverged to varying degrees the PAM matrices reflect the extrapolation of evolutionary information based on closely related sequences to longer timescales. Since scoring information for the PAM and BLOSUM matrices were generated in very different ways the numbers associated with the matrices have fundamentally different meanings; the numbers for PAM matrices increase for comparisons among more divergent proteins whereas the numbers for the BLOSUM matrices decrease. However, all amino acid substitution matrices can be compared in an information theoretic framework using their relative entropy.
Sources: en.wikipedia.org
In 1844, the Welsh scientist William Robert Grove postulated a relationship between mechanics, heat, light, electricity, and magnetism by treating them all as manifestations of a single "force" (energy in modern terms). In 1846, Grove published his theories in his book The Correlation of Physical Forces. In 1847, drawing on the earlier work of Joule, Sadi Carnot, and Émile Clapeyron, Hermann von Helmholtz arrived at conclusions similar to Grove's and published his theories in his book Über die Erhaltung der Kraft (On the Conservation of Force, 1847). The general modern acceptance of the principle stems from this publication. In 1850, the Scottish mathematician William Rankine first used the phrase the law of the conservation of energy for the principle. In 1877, Peter Guthrie Tait claimed that the principle originated with Sir Isaac Newton, based on a creative reading of propositions 40 and 41 of the Philosophiae Naturalis Principia Mathematica. This is now regarded as an example of Whig history.
==== Middle East ==== In Arab countries, dill seed, called ain jaradeh (grasshopper's eye), is used as a spice in cold dishes such as fattoush, and pickles. In Arab countries of the Persian Gulf, dill is called 'shibint' and is used mostly in fish dishes. In Egypt, dillweed is commonly used to flavour cabbage dishes, including mahshi koronb (stuffed cabbage leaves).
A process in which a person is given important facts about a medical procedure or treatment, a clinical trial, or genetic testing before deciding whether or not to participate. It also includes informing the patient when there is new information that may affect his or her decision to continue. Informed consent includes information about the possible risks, benefits, and limits of the procedure, treatment, trial, or genetic testing. (NCI) The process of learning the key facts about a clinical trial before deciding whether or not to participate. It is also a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study. (NLM) A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form. (ICH E6) Informed consent document
In May 2025, the government announced this decision, citing a worsening global economic outlook and the need to reallocate the remaining 157-billion-baht budget to more urgent stimulus measures, such as infrastructure development and tourism promotion. Paetongtarn has publicly insisted that the postponement is not a cancellation and that the government remains committed to fulfilling its promise once economic conditions improve. The policy has been a focal point of her premiership, drawing both support for its potential to aid households and strong criticism from economists for its high cost and debated effectiveness as a stimulus tool.
Sources: en.wikipedia.org
=== Weight-bearing activity === The results produced by aerobic activity were repeated in 1999 where for 12 weeks, weight-bearing exercise was added for patients not exhibiting marked physical incapacity as measured by the Functional Index in Myositis (see Functional Assessment section). Confirmed by MRI and muscle biopsy, both the 1998 and 1999 studies showed that there were no significant changes in levels of creatine kinase and aldolase, and no increase in muscle inflammation. In 2001, 22 patients were placed on a three-week physical therapy and exercise program, and found that creatine kinase levels actually dropped in 20 of the patients. The longest study to date was a six-month exercise program demonstrating a significant improvement in exercise capacity, VO2, isokinetic strength, and the ability to perform daily tasks compared to controls.
If a company transforms from a member state corporation to incorporate under the European Company Regulation 2001, employees are entitled to no less favourable representation than under the member state's existing board participation laws. This is practically important as a majority of EU member states require employee representation on company boards. Fourth, minimum job security rights are provided by three Directives. The Collective Redundancies Directive 1998 specifies that minimum periods of notice and consultation occur if more than a set number of jobs in a workplace are at risk. The Transfers of Undertakings Directive 2001 require that staff retain all contractual rights, unless there is an independent economic, technical or organisational reason, if their workplace is sold from one company to another. Last, the Insolvency Protection Directive 2008 requires that employees' wage claims are protected in case their employer falls insolvent. This last Directive gave rise to Francovich v Italy, where the Court of Justice affirmed that member states which fail to implement the minimum standards in EU Directives are liable to pay compensation to employees who should have rights under them.
=== Cardiac === In dermatomyositis, patients can develop myocarditis and cardiac conduction system abnormalities which may be detected if the patient undergoes special testing. However, these abnormalities typically have no symptoms or clinical consequences. More rarely, these abnormalities can cause greater issues and lead to arrhythmias, heart failure, or damage to heart valves. For those dermatomyositis patients who do have cardiac symptoms caused by the disease, their clinical course may be much worse than usual.
Sources: en.wikipedia.org
Multiple freezing and thawing events can cause aggregation, precipitation, or loss of soluble peptide. Dividing a solution into single-use aliquots before freezing reduces this risk. If multiple cycles are unavoidable, stability should be checked after thawing.
Low-binding polypropylene tubes are often used because some peptides adsorb to glass or standard plastic. The choice depends on peptide hydrophobicity and charge. Containers should be clean, sterile when needed, and compatible with the solvent.
Reverse-phase chromatography can assess purity and retention time, while mass spectrometry confirms molecular mass. These methods can detect degradation products and sequence-related impurities. Results are compared with a reference sample or initial analysis.
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.